Okazaki N, Yoshino M, Yoshida T, Suzuki M, Moriyama N, Takayasu K, et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer. 1989;63:2207–10.
Arai T, Kuroishi T, Saito Y, Kurita Y, Naruke T, Kaneko M. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol. 1994;24:199–204.
Furukawa H, Iwata R, Moriyama N. Growth rate of pancreatic adenocarcinoma: initial clinical experience. Pancreas. 2001;22:366–9.
Kuroishi T, Tominaga S, Morimoto T, Tashiro H, Itoh S, Watanabe H, et al. Tumor growth rate and prognosis of breast cancer mainly detected by mass screening. Jpn J Cancer Res. 1990;81:454–62.
Spratt JS Jr, Spratt TL. Rates of growth of pulmonary metastases and host survival. Ann Surg. 1964;159:161–71.
Stensjoen AL, Solheim O, Kvistad KA, Haberg AK, Salvesen O, Berntsen EM. Growth dynamics of untreated glioblastomas in vivo. Neuro-Oncology. 2015;17:1402–11.
Shackney SE, McCormack GW, Cuchural GJ Jr. Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. Ann Intern Med. 1978;89:107–21.
Ollila DW, Stern SL, Morton DL. Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol. 1998;69:206–11.
Singh AP, Shah DK. Application of a PK-PD modeling and simulation-based strategy for clinical translation of antibody-drug conjugates: a case study with Trastuzumab Emtansine (T-DM1). AAPS J. 2017;19:1054–70.
Schwartz M. A biomathematical approach to clinical tumor growth. Cancer. 1961;14:1272–94.
Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res. 2007;67:3970–5.
Gutman SI, Piper M, Grant MD, Basch E, Oliansky DM, Aronson N. Progression-free survival: what does it mean for psychological well-being or quality of life? Rockville, MD: Agency for Healthcare Research and Quality; 2013. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.
Magazines T, Savers S. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Biotechnol Law Rep. 2007;26:375–86.
World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979. http://www.who.int/iris/handle/10665/37200
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.
R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2016. https://www.R-project.org/
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588–93.
Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21:54–9.
Dutang MLD-MC. Fitdistrplus: an R package for fitting distributions. J Stat Softw. 2015;64:1–34.
Therneau TM. A package for survival analysis in S. version 2.38. 2015. https://CRAN.Rproject.org/package=survival
Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31:482–9.
Oda T, Miyao N, Takahashi A, Yanase M, Masumori N, Itoh N, et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int J Urol. 2001;8:473–7.
Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol. 1997;65:284–97.
Eskelin S, Pyrhonen S, Summanen P, Hahka-Kemppinen M, Kivela T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000;107:1443–9.
Malaise EP, Chavaudra N, Charbit A, Tubiana M. Relationship between the growth rate of human metastases, survival and pathological type. Eur J Cancer. 1974;10:451–9.
Garland LH, Coulson W, Wollin E. The rate of growth and apparent duration of untreated primary bronchial carcinoma. Cancer. 1963;16:694–707.
Breur K. Growth rate and radiosensitivity of human tumours. I Growth rate of human tumours. Eur J Cancer. 1966;2:157–71.
Gomez-de la Fuente FJ, Martinez-Rodriguez I, de Arcocha-Torres M, Quirce R, Jimenez-Bonilla J, Martinez-Amador N, et al. Contribution of (11)C-Choline PET/CT in prostate carcinoma biochemical relapse with serum PSA level below 1 ng/ml. Rev Esp Med Nucl Imagen Mol. 2018;37:156–62.
Watanabe H. Relapse of prostate cancer from the viewpoint of total gland volume kinetics theory. Asian J Androl. 2015;17:904–7 discussion 7.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.
Hutchinson L, Kirk R. High drug attrition rates--where are we going wrong? Nat Rev Clin Oncol. 2011;8:189–90.
Begley CG, Ellis LM. Drug development: raise standards for preclinical cancer research. Nature. 2012;483:531–3.
Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012;39:643–59.
Havelaar IJ, Sugarbaker PH, Vermess M, Miller DL. Rate of growth of intraabdominal metastases from colorectal cancer. Cancer. 1984;54:163–71.
Plesnicar S, Klanjscek G, Modic S. Actual doubling time values of pulmonary metastases from malignant melanoma. Aust N Z J Surg. 1978;48:23–5.
Carlson JA. Tumor doubling time of cutaneous melanoma and its metastasis. Am J Dermatopathol. 2003;25:291–9.
Fujimoto N, Sugita A, Terasawa Y, Kato M. Observations on the growth rate of renal cell carcinoma. Int J Urol. 1995;2:71–6.
Ozono S, Miyao N, Igarashi T, Marumo K, Nakazawa H, Fukuda M, et al. Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer. Jpn J Clin Oncol. 2004;34:82–5.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56.